vs
NeuroPace Inc（NPCE）与OR Royalties Inc.（OR）财务数据对比。点击上方公司名可切换其他公司
OR Royalties Inc.的季度营收约是NeuroPace Inc的1.8倍（$46.7M vs $26.6M）
NeuroPace Inc是一家专注于神经调控技术的医疗科技企业，核心产品为可植入式响应神经刺激系统，主要用于治疗药物难治性癫痫，通过与医疗机构合作，为北美及部分全球市场的患者提供个性化治疗方案，降低癫痫发作频率。
OR Royalties Inc.是一家加拿大矿业特许权企业，持有金矿、银矿及钻石矿的特许权权益，主要以冶炼厂净回报权和金属流形式运营。其前身为奥西斯科矿业，总部位于魁北克省蒙特利尔，股票在多伦多证券交易所及纽约证券交易所挂牌交易。
NPCE vs OR — 直观对比
营收规模更大
OR
是对方的1.8倍
$26.6M
损益表 — Q4 FY2025 vs Q2 FY2022
| 指标 | | |
|---|---|---|
| 营收 | $26.6M | $46.7M |
| 净利润 | $-2.7M | — |
| 毛利率 | 77.4% | — |
| 营业利润率 | -6.6% | — |
| 净利率 | -10.3% | — |
| 营收同比 | 23.9% | — |
| 净利润同比 | 48.0% | — |
| 每股收益（稀释后） | $-0.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NPCEOR
| Q4 25 | $26.6M | — | ||
| Q3 25 | $27.4M | — | ||
| Q2 25 | $23.5M | — | ||
| Q1 25 | $22.5M | — | ||
| Q4 24 | $21.5M | — | ||
| Q3 24 | $21.1M | — | ||
| Q2 24 | $19.3M | — | ||
| Q1 24 | $18.1M | — |
净利润NPCEOR
| Q4 25 | $-2.7M | — | ||
| Q3 25 | $-3.5M | — | ||
| Q2 25 | $-8.7M | — | ||
| Q1 25 | $-6.6M | — | ||
| Q4 24 | $-5.3M | — | ||
| Q3 24 | $-5.5M | — | ||
| Q2 24 | $-7.5M | — | ||
| Q1 24 | $-8.9M | — |
毛利率NPCEOR
| Q4 25 | 77.4% | — | ||
| Q3 25 | 77.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 77.0% | — | ||
| Q4 24 | 75.4% | — | ||
| Q3 24 | 73.2% | — | ||
| Q2 24 | 73.4% | — | ||
| Q1 24 | 73.6% | — |
营业利润率NPCEOR
| Q4 25 | -6.6% | — | ||
| Q3 25 | -9.5% | — | ||
| Q2 25 | -29.0% | — | ||
| Q1 25 | -22.9% | — | ||
| Q4 24 | -17.0% | — | ||
| Q3 24 | -20.1% | — | ||
| Q2 24 | -32.4% | — | ||
| Q1 24 | -41.6% | — |
净利率NPCEOR
| Q4 25 | -10.3% | — | ||
| Q3 25 | -12.8% | — | ||
| Q2 25 | -36.8% | — | ||
| Q1 25 | -29.3% | — | ||
| Q4 24 | -24.5% | — | ||
| Q3 24 | -25.9% | — | ||
| Q2 24 | -39.0% | — | ||
| Q1 24 | -49.2% | — |
每股收益（稀释后）NPCEOR
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.26 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.16 | — | ||
| Q3 24 | $-0.19 | — | ||
| Q2 24 | $-0.26 | — | ||
| Q1 24 | $-0.32 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $61.1M | — |
| 总债务越低越好 | — | $222.8M |
| 股东权益账面价值 | $19.0M | $1.3B |
| 总资产 | $105.6M | — |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资NPCEOR
| Q4 25 | $61.1M | — | ||
| Q3 25 | $60.0M | — | ||
| Q2 25 | $62.1M | — | ||
| Q1 25 | $66.3M | — | ||
| Q4 24 | $52.8M | — | ||
| Q3 24 | $56.8M | — | ||
| Q2 24 | $55.5M | — | ||
| Q1 24 | $58.9M | — |
股东权益NPCEOR
| Q4 25 | $19.0M | — | ||
| Q3 25 | $18.5M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $24.3M | — | ||
| Q4 24 | $8.0M | — | ||
| Q3 24 | $9.8M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $14.3M | — |
总资产NPCEOR
| Q4 25 | $105.6M | — | ||
| Q3 25 | $107.3M | — | ||
| Q2 25 | $106.1M | — | ||
| Q1 25 | $110.2M | — | ||
| Q4 24 | $94.6M | — | ||
| Q3 24 | $96.3M | — | ||
| Q2 24 | $94.4M | — | ||
| Q1 24 | $98.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $506.0K | — |
| 自由现金流经营现金流 - 资本支出 | $409.0K | — |
| 自由现金流率自由现金流/营收 | 1.5% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-11.3M | — |
8季度趋势，按日历期对齐
经营现金流NPCEOR
| Q4 25 | $506.0K | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-7.5M | — | ||
| Q4 24 | $-4.8M | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-3.9M | — | ||
| Q1 24 | $-7.5M | — |
自由现金流NPCEOR
| Q4 25 | $409.0K | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-7.5M | — | ||
| Q4 24 | $-4.8M | — | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $-4.0M | — | ||
| Q1 24 | $-7.6M | — |
自由现金流率NPCEOR
| Q4 25 | 1.5% | — | ||
| Q3 25 | -7.2% | — | ||
| Q2 25 | -9.6% | — | ||
| Q1 25 | -33.4% | — | ||
| Q4 24 | -22.5% | — | ||
| Q3 24 | -8.7% | — | ||
| Q2 24 | -20.6% | — | ||
| Q1 24 | -42.1% | — |
资本支出强度NPCEOR
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.6% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
